AVROBIO (AVRO)
(Delayed Data from NSDQ)
$1.51 USD
+0.10 (7.09%)
Updated May 24, 2024 04:00 PM ET
After-Market: $1.51 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
AVROBIO, Inc. [AVRO]
Reports for Purchase
Showing records 81 - 100 ( 114 total )
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
2020 Catalyst Calendar and Top Picks Across Mid, Small, and Micro Caps
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
3Q19; Updated Fabry Next up at WORLDSymposium, and Maybe Cytinosis Too
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Recap; Execution on its Gaucher Program Remains the Key Driver During 2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - 2019 PacGrow Healthcare Conference: Day 2 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
1H19 Recap: Baton Handed to LV2; Target Lowered to $35 Reflecting Recent Financing
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
2Q19; Initial Patient Dosing for Gaucher, Cystinosis Expected This Year
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Emerging Clinical Profile Supports a Future RMAT Designation
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Fabry Update Shows Positive Biopsy Data, Continued Long- Term Clinical Benefit
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Interim Fabry Update and Rollout of the Plato Platform Remain Key Inflection Points During 2H19
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
FY18 Financials; Gaucher and Cystinosis on Track to Start This Year
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AVROBIO, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.